<DOC>
	<DOCNO>NCT02820857</DOCNO>
	<brief_summary>Poorly differentiate neuroendocrine carcinoma ( NEC ) sub-group aggressive neuroendocrine neoplasm ( NEN ) . The common primary site broncho-pulmonary digestive . The gastroentero-pancreatic NECs ( GEP-NEC ) represent 7-21 % NENs . Recent data initial presentation GEP-NEC report two retrospective study French cohort study . No standard second-line treatment define NECs . Despite negative prognosis , NECs certain amount chemosensitivity , close bronchial NECs . Multiple-drug therapy Folfiri , Folfox , single drug treatment temozolomide propose option low level proof Bevacizumab associate cytotoxic chemotherapy show promising result well differentiated neuroendocrine tumor ( NET ) , know hypervascular . The efficacy bevacizumab also suggest patient NEC , never context phase II study . Its combination Folfiri efficient well tolerate metastatic colorectal cancer . The combination Folfiri-bevacizumab potentially represent optimized treatment compare chemotherapy Folfiri . No phase II III study report result patient , on-going phase II III trial identify date . The main objective study show , failure first-line chemotherapy use platinum-etoposide , combination Folfiri-bevacizumab allow significant prolongation overall survival adult patient GEP-NEC .</brief_summary>
	<brief_title>Assessment Efficacy Bevacizumab Combination With Folfiri Second-line Treatment Patients Suffering From Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma Unknown Gastroentero-pancreatic Primary Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Man woman age ≥ 18 year old , Poorly differentiate neuroendocrine carcinoma ( NEC ) GEP primary unknown primary cancer , locally advanced and/or metastatic ( accord WHO 2010 ) , Centralized review diagnostic consulting pathologist specialize NET ( TENPATH network ) , Recommendation secondline chemotherapy progression , document use RECIST criterion v.1.1 , firstline chemotherapy treatment cisplatin ( carboplatin ) + etoposide event progression 6 month follow discontinuation firstline treatment , Patients present least one measurable target lesion accord RECIST criterion v.1.1 , area previously irradiate , General condition ≤ 2 ( WHO ) , Patient sign informed consent form . 1 . Relating tumor , patient , previous treatment : Well differentiate gastroenteropancreatic ( GEP ) neuroendocrine tumor ( NET ) ( G1 G2 accord WHO 2010 ) , Mixed tumor , Firstline chemotherapy cisplatin ( carboplatin ) etoposide , All malignant disease three year randomization , exception basal cell carcinoma situ cervical cancer treat curative purpose , A pregnant breastfeeding woman , Lack efficient contraception ( men woman reproductive age ) , All medical , geographical , social , psychological condition legal situation allow patient finish study sign inform consent form , 2 . Relating chemotherapy ( Folfiri ) : Any follow uncontrolled progressive disease 6 month randomization : liver failure , renal insufficiency , respiratory distress , congestive heart failure ( NYHA IIIIV ) , unstable angina , myocardial infarction , significant arrhythmia , Known deficiency dihydropyrimidine dehydrogenase , Known Gilbert 's syndrome , Total bilirubin level &gt; 1.5x upper limit normal ( ULN ) ; AST ( Aspartate transaminase ) and/or ALT ( Alanine transaminase ) &gt; 5x ULN ; TP &lt; 50 % ; Neutrophils &lt; 1.5x109/l , platelet &lt; 100x109/l , hemoglobin &lt; 10 g/dl , Chronic uncontrolled diarrhea , unresolved intestinal occlusion subocclusion , History anaphylactic reaction know intolerance atropine ( sulfate ) loperamide antiemetic administer association Folfiri , All treatment concomitant anticonvulsive agent , CYP3A4 inducer ( phenytoin , phenobarbital , carbamazepine ) , discontinue least 7 day , 3 . Relating bevacizumab : Uncontrolled brain metastasis ( local treatment ) , All uncontrolled progressive disease within 1 month prior randomization : grade 34 gastrointestinal bleeding ( peptic ulcer , erosive esophagitis gastritis ) , infectious disease intestinal inflammation , diverticulitis , pulmonary embolism uncontrolled thromboembolic event , Uncontrolled high blood pressure define systolic blood pressure &gt; 140 mmHg diastolic pressure &gt; 90 mmHg , Patients receive anticoagulant treatment unstable dose vitamin K antagonist treatment , and/or abnormal INR ( &gt; 3 ) four week randomization , Verified proteinuria equal 1g/24 hour measure 24 hour urine urinary protein dipstick control equal 2+ , Creatinine clearance ( MDRD ) &lt; 50 ml/min . Hypersensitivity active substance excipients . Hypersensitivity Chinese Hamster Ovary ( CHO ) cell product recombinant human humanise antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Gastroentero-pancreatic neuroendocrine carcinoma</keyword>
	<keyword>Second-line treatment</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>Folfiri</keyword>
</DOC>